Misoprostol sublingual 600 μg to be tested for additive effect on postpartum hemorrhage reduction

Postpartum haemorrhage (PPH) remains a leading cause of maternal mortality globally, with conventional treatments often proving insufficient. Uterine atony is a primary contributor to PPH, necessitating effective uterotonic agents. While oxytocin and ergometrine are standard, misoprostol offers advantages like heat stability and a longer shelf life, making it particularly appealing in resource-limited settings. Uncontrolled reports and small trials suggest misoprostol may have an additive effect, but robust, large-scale evidence is critically lacking. This gap creates a serious risk of widespread, undocumented use, highlighting the urgent need for rigorous research into its effectiveness and safety.

This paper describes the design of a randomized controlled trial (RCT) to investigate misoprostol's efficacy in postpartum hemorrhage (PPH). Women experiencing measured blood loss greater than or equal to 500 mls after delivery in four Karachi hospitals, who require additional uterotonics after routine syntocinon, will be enrolled. Participants will be randomized to receive either misoprostol 600 μg sublingually or a placebo, in addition to their locally routine PPH treatment. The primary outcome measure will be blood loss greater than or equal to 500 mls after enrolment, comparing the two treatment arms.

This abstract outlines the design of a proposed randomized controlled trial, not its completed findings. Therefore, no results are available yet. The study is designed to rigorously assess whether misoprostol 600 μg sublingually provides an additive benefit in reducing postpartum hemorrhage (PPH). The intervention is planned for women who have experienced blood loss greater than or equal to 500 mls after delivery and have already received routine syntocinon and additional conventional uterotonics.

The primary outcome measure for this proposed trial will be blood loss greater than or equal to 500 mls after enrolment, comparing the misoprostol arm to a placebo arm. This design aims to provide crucial, evidence-based data to either support or refute the widespread use of misoprostol as an adjunct in PPH management, particularly in settings where its use is currently based on limited evidence.